Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Satish Dasari

Interventional Pain Medicine Munster, IN Medical Doctor

NPI 1811996606 CMS profile 127556

8840 Calumet Ave, Suite 103, Munster, IN 46321

Open in the dashboard

General payments

$4,758

136 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Satish Dasari of Munster, IN is reported in the CMS Open Payments database as having received $4,758 across 136 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $799 24
2024 General $393 12
2023 General $674 23
2022 General $427 10
2021 General $353 20
2020 General $1,280 17
2019 General $834 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Satish Dasari
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Satish Dasari were reported at $799. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Satish Dasari Interventional Pain Medicine median Middle half National median
2019 $834 $684 $216–$2,079 $163
2020 $1,280 $382 $122–$1,109 $114
2021 $353 $552 $167–$1,554 $132
2022 $427 $605 $187–$1,924 $149
2023 $674 $671 $195–$1,915 $160
2024 $393 $684 $206–$1,837 $164
2025 $799 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,122 48 payments
  2. Nalu Medical, Inc. $856 4 payments
  3. Abbott Laboratories $674 9 payments
  4. Boston Scientific Corporation $271 11 payments
  5. Medtronic USA, Inc. $175 12 payments
  6. Vertos Medical, Inc. $164 2 payments
  7. Globus Medical, Inc. $142 1 payment
  8. Scilex Pharmaceuticals Inc. $136 7 payments
  9. Painteq LLC $135 1 payment
  10. ANI Pharmaceuticals, Inc. $125 1 payment
  11. Other $958 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,072 133 payments
  2. Travel and Lodging $687 3 payments
Products named General payments · program years 2019–2025
  1. Nalu Neurostimulation System $856 4 payments
  2. INTELLIS ADAPTIVESTIM $744 22 payments
  3. Proclaim Family of SCS IPGs $504 6 payments
  4. mild Device Kit $164 2 payments
  5. Senza $142 1 payment
  6. PAINTEQ $135 1 payment
  7. MYSTIM $131 8 payments
  8. PURIFIED CORTROPHIN GEL $125 1 payment
  9. ReActiv8 $124 2 payments
  10. VANTA ADAPTIVESTIM $117 8 payments
  11. Other $1,887 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

70

Median for Pain Management: 951

Drug cost

$671

Median for Pain Management: $26,034

Branded share of claims

44.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 31 $461
Gabapentin Generic 12 $91
Tizanidine Hcl Generic 14 $72
Tramadol Hcl Generic 13 $47

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$129,942

Of which drugs: $464

Medicare patients

600

Average age 74

Services billed

1,745

369 women, 231 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 35%
Diabetes 34%
Depression 27%
Chronic kidney disease 26%
COPD 23%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 74 $56

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record